Melanoma and other Skin Cancers Parallel Session

Moderator(s)

• 

  Ryan Fields, MD

  Chief, Surgical Oncology; Professor of Surgery
  Barnes-Jewish Hospital and the Alvin J. Siteman Cancer Center at Washington University School of Medicine
  St.Louis, MO, United States
• 

  Charlotte Ariyan, MD, PhD

  Associate Attending, Gastric & Mixed Tumor Service
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States

Presentations:

• 1:01 PM – 1:09 PM CST

  49: Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients
  

  Abstract Presenter: Marc D. Moncrieff, MD FRCS(Plast.) – Norfolk & Norwich University Hospital
• 1:09 PM – 1:11 PM CST

  49: Q&A
  

  Abstract Presenter: Marc D. Moncrieff, MD FRCS(Plast.) – Norfolk & Norwich University Hospital
• 1:11 PM – 1:19 PM CST

  52: Stage Migration as a Consequence of Omitting Completion Lymph Node Dissection for Melanoma
  

  Abstract Presenter: Zachary J. Senders, MD – University of Louisville
• 1:19 PM – 1:21 PM CST

  52: Q&A
  

  Abstract Presenter: Zachary J. Senders, MD – University of Louisville
• 1:21 PM – 1:29 PM CST

  48: Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-positive Sentinel Node Melanoma: The Role of the First Post-operative Ultrasound
  

  Abstract Presenter: Jennifer Keller, MD – Saint John's Providence Cancer Institute
• 1:29 PM – 1:31 PM CST

  48: Q&A
  

  Abstract Presenter: Jennifer Keller, MD – Saint John's Providence Cancer Institute
• 1:31 PM – 1:39 PM CST

  50: Sentinel Lymph Node Biopsy in Patients with t1a Cutaneous Malignant Melanoma
  

  Abstract Presenter: Adrienne B. Shannon, MD – Hospital of the University of Pennsylvania
• 1:39 PM – 1:41 PM CST

  50: Q&A
  

  Abstract Presenter: Adrienne B. Shannon, MD – Hospital of the University of Pennsylvania
• 1:41 PM – 1:49 PM CST

  51: Spatial Biology Analysis Reveals the Location and Activation of B Cells in Sentinel Lymph Nodes Correlate with Prognosis in Melanoma Patients
  

  Abstract Presenter: Aaron D. Therien, MS, BS – Duke University Medical Center
• 1:49 PM – 1:51 PM CST

  51: Q&A
  

  Abstract Presenter: Aaron D. Therien, MS, BS – Duke University Medical Center
• 1:51 PM – 1:59 PM CST

  46: C-terminal hsp90 Inhibitors Overcome MEK and BRAF Inhibitor Resistance in Melanoma
  

  Abstract Presenter: Katie K. Spielbauer, MD – Michigan Medicine
• 1:59 PM – 2:01 PM CST

  46: Q&A
  

  Abstract Presenter: Katie K. Spielbauer, MD – Michigan Medicine
• 2:01 PM – 2:09 PM CST

  47: Neoadjuvant Systemic Therapy for Merkel Cell Carcinoma: A Tertiary Referral Center Experience
  

  Abstract Presenter: Russell G. Witt, MD, M.A.S. – University of Texas MD Anderson Cancer Center
• 2:09 PM – 2:11 PM CST

  47: Q&A
  

  Abstract Presenter: Russell G. Witt, MD, M.A.S. – University of Texas MD Anderson Cancer Center